logo
Plus   Neg
Share
Email

Myriad: FDA Approves MyChoice CDx Test As Companion Diagnostics For Lynparza

Myriad Genetics, Inc. (MYGN) announced the FDA approved the myChoice CDx test for use as a companion diagnostic by healthcare professionals to identify advanced ovarian cancer patients with positive homologous recombination deficiency status, who are eligible or may become eligible, for first-line maintenance treatment with Lynparza (olaparib) in combination with bevacizumab.

Lynparza is a PARP inhibitor jointly developed and commercialized by AstraZeneca and Merck. Myriad has been collaborating with AstraZeneca since 2007 on the development of companion diagnostics for Lynparza.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT